Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06744920 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT06744920 · ClinicalTrials.gov record · last posted 2026-07-29

A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis

Name: A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis — clinical trial record (NCT06744920)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: RELIEVE

StatusRecruiting

PhasePhase 3

SponsorNovartis Pharmaceuticals

Started2025-02-07

View on ClinicalTrials.gov ↗

from the ClinicalTrials.gov record

A study to evaluate the efficacy, safety and tolerability of Remibrutinib versus placebo in adult patients with Generalized Myasthenia Gravis who are on stable, standard-of-care (SOC) treatment.

Protocol amendment history 2 changes detected by DataLookout

2026-06-02

Trial sites expanded: 101 → 129 locations

2026-04-25

Trial sites expanded: 95 → 99 locations

Trial Details

NCT Number	NCT06744920
Lead Sponsor	Novartis Pharmaceuticals
Conditions	Generalized Myasthenia Gravis
Enrollment	180 participants
Start Date	2025-02-07
Primary Completion	2028-02-25 (estimated)
Study Completion	2033-02-26 (estimated)
Updated on ClinicalTrials.gov	2026-07-29